Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 8/20 | 0.66 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 4/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 2/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19073287 | 0.79 | PDPK1 (0.64) | PDPK1PARP1PIM1PIM3CLK4 | |
| SCHEMBL358129 | 0.79 | PDPK1 (1.00) | PDPK1PARP1PIM1PIM3CLK4 | |
| SCHEMBL7228363 | 0.77 | PDPK1 (0.40) | PDPK1PARP1DYRK1ACSNK2A1NPC1 | |
| SCHEMBL1850150 | 0.73 | PDPK1 (1.00) | PDPK1PIM1PIM3CLK4NPC1 | |
| SCHEMBL7236463 | 0.72 | PDPK1 (0.46) | PDPK1PARP1PIM1PIM3CLK4 | |
| SCHEMBL16479488 | 0.72 | PDPK1 (0.39) | PDPK1PARP1GSK3BCSNK2A1ALDH1A1 | |
| SCHEMBL17969217 | 0.71 | PDPK1 (0.74) | PDPK1NPC1RAB9A | |
| SCHEMBL4208195 | 0.71 | PDPK1 (0.74) | PDPK1PIM1PIM3CLK4DAPK3 | |
| SCHEMBL3784826 | 0.69 | RAB9A (0.55) | PDPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL28831137 | 0.69 | PDPK1 (0.40) | PDPK1PARP1DYRK1ACSNK2A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114524826-A | Preparation process of 7-bromo-4-chlorothiophene [3,2-d ] pyrimidine | 郑州猫眼农业科技有限公司 | 2022-05-24 | — | — | CN | claimed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | claimed |
| EP-4363424-B1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3617213-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-02-19 | — | — | EP | disclosed |
| US-20250051351-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2025-02-13 | — | — | US | disclosed |
| US-11999749-B2 | Synthesis of a bis-mesylate salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide and intermediates thereto | GENENTECH, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4363424-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | Genentech, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117580840-A | Synthesis of bis-mesylate salt of 4-amino-N- (1- ((3-chloro-2-fluorophenyl) amino) -6-methylisoquinolin-5-yl) thieno [3,2-D ] pyrimidine-7-carboxamide and intermediates thereof | 基因泰克公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230028651-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230028651-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2023278981-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-1773843-A4 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | UNIV TEXAS (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
| US-7285556-B2 | Thienopyrimidine-based inhibitors of the src family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1773843-A1 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | The Board of Regents of The University of Texas System (US) | 2007-04-18 | — | — | EP | disclosed |
| US-RE39267-E1 | Thienopyrimidine-based inhibitors of the SRC family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-09-05 | — | — | US | disclosed |
| WO-2006014404-A1 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | disclosed |
| US-20040077663-A1 | Thienopyrimidine-based inhibitors of the src family | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-22 | — | — | US | disclosed |
| US-6503914-B1 | Thienopyrimidine-based inhibitors of the Src family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | SRC, LCK, FYN | PDPK1 351/4885PARP1 2264/4885PIM1 205/4885 |
| US-20250051351-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | BRAF, RAF1, KRAS | PDPK1 777/4885PARP1 649/4885PIM1 680/4885 |
| US-20230028651-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | BRAF, RAF1, KRAS | PDPK1 768/4885PARP1 469/4885PIM1 648/4885 |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | PDPK1 13/4885PARP1 468/4885PIM1 1/4885 |
| US-11999749-B2 | Synthesis of a bis-mesylate salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide and intermediates thereto | BRAF, RAF1, KRAS | PDPK1 777/4885PARP1 624/4885PIM1 689/4885 |
| US-20040077663-A1 | Thienopyrimidine-based inhibitors of the src family | SRC, LCK, FYN | PDPK1 639/4885PARP1 1561/4885PIM1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.